331 related articles for article (PubMed ID: 18450470)
21. IL-1 receptor accessory protein is an essential component of the IL-1 receptor.
Cullinan EB; Kwee L; Nunes P; Shuster DJ; Ju G; McIntyre KW; Chizzonite RA; Labow MA
J Immunol; 1998 Nov; 161(10):5614-20. PubMed ID: 9820540
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury.
Yin H; Huang BJ; Yang H; Huang YF; Xiong P; Zheng F; Chen XP; Chen YF; Gong FL
Biochem Biophys Res Commun; 2006 Dec; 351(4):940-6. PubMed ID: 17097607
[TBL] [Abstract][Full Text] [Related]
23. Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation.
Lipsky BP; Toy DY; Swart DA; Smithgall MD; Smith D
Eur J Immunol; 2012 Jul; 42(7):1863-9. PubMed ID: 22585662
[TBL] [Abstract][Full Text] [Related]
24. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals.
Ho LH; Ohno T; Oboki K; Kajiwara N; Suto H; Iikura M; Okayama Y; Akira S; Saito H; Galli SJ; Nakae S
J Leukoc Biol; 2007 Dec; 82(6):1481-90. PubMed ID: 17881510
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways.
Saluja R; Hawro T; Eberle J; Church MK; Maurer M
J Biol Regul Homeost Agents; 2014; 28(4):575-85. PubMed ID: 25620169
[TBL] [Abstract][Full Text] [Related]
26. Characterization of ST2 transgenic mice with resistance to IL-33.
Ohto-Ozaki H; Kuroiwa K; Mato N; Matsuyama Y; Hayakawa M; Tamemoto H; Tominaga S
Eur J Immunol; 2010 Sep; 40(9):2632-42. PubMed ID: 20662097
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity.
Kim JY; Lim SC; Kim G; Yun HJ; Ahn SG; Choi HS
Oncogene; 2015 Sep; 34(38):4928-38. PubMed ID: 25531326
[TBL] [Abstract][Full Text] [Related]
28. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function.
Hoshino K; Kashiwamura S; Kuribayashi K; Kodama T; Tsujimura T; Nakanishi K; Matsuyama T; Takeda K; Akira S
J Exp Med; 1999 Nov; 190(10):1541-8. PubMed ID: 10562328
[TBL] [Abstract][Full Text] [Related]
29. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases.
Lüthi AU; Cullen SP; McNeela EA; Duriez PJ; Afonina IS; Sheridan C; Brumatti G; Taylor RC; Kersse K; Vandenabeele P; Lavelle EC; Martin SJ
Immunity; 2009 Jul; 31(1):84-98. PubMed ID: 19559631
[TBL] [Abstract][Full Text] [Related]
30. Recombinant ST2 boosts hepatic Th2 response in vivo.
Amatucci A; Novobrantseva T; Gilbride K; Brickelmaier M; Hochman P; Ibraghimov A
J Leukoc Biol; 2007 Jul; 82(1):124-32. PubMed ID: 17412915
[TBL] [Abstract][Full Text] [Related]
31. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer.
Liu X; Zhu L; Lu X; Bian H; Wu X; Yang W; Qin Q
Biochem Biophys Res Commun; 2014 Oct; 453(3):486-92. PubMed ID: 25280997
[TBL] [Abstract][Full Text] [Related]
32. IL-33 causes selective mast cell tolerance to bacterial cell wall products by inducing IRAK1 degradation.
Sandig H; Jobbings CE; Roldan NG; Whittingham-Dowd JK; Orinska Z; Takeuchi O; Akira S; Bulfone-Paus S
Eur J Immunol; 2013 Apr; 43(4):979-88. PubMed ID: 23404570
[TBL] [Abstract][Full Text] [Related]
33. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors.
Taracanova A; Alevizos M; Karagkouni A; Weng Z; Norwitz E; Conti P; Leeman SE; Theoharides TC
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4002-E4009. PubMed ID: 28461492
[TBL] [Abstract][Full Text] [Related]
34. An interleukin-33/ST2 signaling deficiency reduces overt pain-like behaviors in mice.
Magro DA; Hohmann MS; Mizokami SS; Cunha TM; Alves-Filho JC; Casagrande R; Ferreira SH; Liew FY; Cunha FQ; Verri WA
Braz J Med Biol Res; 2013 Jul; 46(7):601-6. PubMed ID: 23903682
[TBL] [Abstract][Full Text] [Related]
35. Crucial and diverse role of the interleukin-33/ST2 axis in infectious diseases.
Rostan O; Arshad MI; Piquet-Pellorce C; Robert-Gangneux F; Gangneux JP; Samson M
Infect Immun; 2015 May; 83(5):1738-48. PubMed ID: 25712928
[TBL] [Abstract][Full Text] [Related]
36. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response.
Bulek K; Swaidani S; Qin J; Lu Y; Gulen MF; Herjan T; Min B; Kastelein RA; Aronica M; Kosz-Vnenchak M; Li X
J Immunol; 2009 Mar; 182(5):2601-9. PubMed ID: 19234154
[TBL] [Abstract][Full Text] [Related]
37. IL-33 exacerbates antigen-induced arthritis by activating mast cells.
Xu D; Jiang HR; Kewin P; Li Y; Mu R; Fraser AR; Pitman N; Kurowska-Stolarska M; McKenzie AN; McInnes IB; Liew FY
Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10913-8. PubMed ID: 18667700
[TBL] [Abstract][Full Text] [Related]
38. Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor.
Fields JK; Kihn K; Birkedal GS; Klontz EH; Sjöström K; Günther S; Beadenkopf R; Forsberg G; Liberg D; Snyder GA; Deredge D; Sundberg EJ
Front Immunol; 2021; 12():779100. PubMed ID: 35003094
[TBL] [Abstract][Full Text] [Related]
39. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes.
Lingel A; Weiss TM; Niebuhr M; Pan B; Appleton BA; Wiesmann C; Bazan JF; Fairbrother WJ
Structure; 2009 Oct; 17(10):1398-410. PubMed ID: 19836339
[TBL] [Abstract][Full Text] [Related]
40. Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.
Bandara G; Beaven MA; Olivera A; Gilfillan AM; Metcalfe DD
Eur J Immunol; 2015 Nov; 45(11):3034-44. PubMed ID: 26256265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
